Publication:
CBP-mediated SMN acetylation modulates Cajal body biogenesis and the cytoplasmic targeting of SMN.

dc.contributor.authorLafarga, Vanesa
dc.contributor.authorTapia, Olga
dc.contributor.authorSharma, Sahil
dc.contributor.authorBengoechea, Rocio
dc.contributor.authorStoecklin, Georg
dc.contributor.authorLafarga, Miguel
dc.contributor.authorBerciano, Maria T
dc.contributor.funderEuropean Union (EU)
dc.contributor.funderFundAME (Spain)
dc.contributor.funderCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Spain
dc.date.accessioned2025-01-21T11:48:48Z
dc.date.available2025-01-21T11:48:48Z
dc.date.issued2018-02
dc.description.abstractThe survival of motor neuron (SMN) protein plays an essential role in the biogenesis of spliceosomal snRNPs and the molecular assembly of Cajal bodies (CBs). Deletion of or mutations in the SMN1 gene cause spinal muscular atrophy (SMA) with degeneration and loss of motor neurons. Reduced SMN levels in SMA lead to deficient snRNP biogenesis with consequent splicing pathology. Here, we demonstrate that SMN is a novel and specific target of the acetyltransferase CBP (CREB-binding protein). Furthermore, we identify lysine (K) 119 as the main acetylation site in SMN. Importantly, SMN acetylation enhances its cytoplasmic localization, causes depletion of CBs, and reduces the accumulation of snRNPs in nuclear speckles. In contrast, the acetylation-deficient SMNK119R mutant promotes formation of CBs and a novel category of promyelocytic leukemia (PML) bodies enriched in this protein. Acetylation increases the half-life of SMN protein, reduces its cytoplasmic diffusion rate and modifies its interactome. Hence, SMN acetylation leads to its dysfunction, which explains the ineffectiveness of HDAC (histone deacetylases) inhibitors in SMA therapy despite their potential to increase SMN levels.
dc.description.peerreviewed
dc.description.tableofcontentsThe authors are indebted to Prof. Angus I. Lamond, Prof. Greg Matera, Prof. Maria Carmo-Fonseca and Prof. Larry Gerace for reagents, and Renate Voit (DKFZ) for generously providing plasmids. We would also like to acknowledge Dr. Thomas Ruppert and his team from the ZMBH (Zentrum fur Molekulare Biologie der Universitat Heidelberg) Mass Spectrometry Core Facility and Dr. Fidel Madrazo from the IDIVAL (Instituto de Investigacion Sanitaria Valdecilla) Microscopy Facility. This work was supported by the following Grants: "Direccion General de Investigacion" (BFU2014-54754-P) and "Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas" (CIBERNED; CB06/05/0037) Spain. V. Lafarga was supported by a Marie Curie Intra-European Fellowship (mirnaAGOddr, Grant nr. 300384). O. Tapia was supported by a Postdoctoral Fellowship from SMA Europe and FundAME (Spain).
dc.format.number3
dc.format.page527-546
dc.format.volume75
dc.identifier.citationCell Mol Life Sci . 2018 Feb;75(3):527-546.
dc.identifier.journalCell Mol Life Sci
dc.identifier.pubmedID28879433
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26085
dc.language.isoeng
dc.publisherSpringuer
dc.relation.publisherversionhttp://doi: 10.1007/s00018-017-2638-2. Epub 2017 Sep 6.
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómica
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCBP
dc.subjectCajal bodies
dc.subjectHDAC inhibitor
dc.subjectNuclear speckles
dc.subjectProtein acetylation
dc.subjectSMA
dc.subjectSMN
dc.subjectSMN complex
dc.subjectSMN interactome
dc.subjectSnRNP
dc.titleCBP-mediated SMN acetylation modulates Cajal body biogenesis and the cytoplasmic targeting of SMN.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication259ea37c-41fc-4f09-b2f0-a909a24d048b
relation.isAuthorOfPublication.latestForDiscovery259ea37c-41fc-4f09-b2f0-a909a24d048b

Files